Literature DB >> 33128337

New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding.

Maddalena Napolitano1, Angelo Ruggiero2, Giuseppina Fontanella2, Gabriella Fabbrocini2, Cataldo Patruno3.   

Abstract

Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease. Systemic treatment is usually mandatory in moderate-to-severe AD of the adult; these patients need to be informed about safe and effective management of AD also regarding the reproduction. Treating a pregnant woman with AD with systemic drugs may affect the unborn child. While effects of traditional systemic treatments for AD on female fertility, pregnancy, and breastfeeding are largely known, data about new emergent therapies for AD are still poor. Treating pregnant or lactating women with AD can be a challenge since no large clinical studies on its possible effects and side-effects on conception, pregnancy, the unborn child and lactation are currently available for new AD treatments.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  atopic dermatitis; atopic dermatitis treatment; dupilumab

Mesh:

Substances:

Year:  2020        PMID: 33128337     DOI: 10.1111/dth.14475

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  5 in total

Review 1.  Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP).

Authors:  Elena Galli; Anna Belloni Fortina; Giampaolo Ricci; Nunzia Maiello; Iria Neri; Ermanno Baldo; Irene Berti; Domenico Bonamonte; Lucetta Capra; Elena Carboni; Rossella Carello; Francesca Caroppo; Giovanni Cavagni; Iolanda Chinellato; Francesca Cipriani; Pasquale Comberiati; Andrea Diociaiuti; Vito Di Lernia; Marzia Duse; Cesare Filippeschi; Arianna Giannetti; Mattia Giovannini; Amelia Licari; Gian Luigi Marseglia; Manuela Pace; Annalisa Patrizi; Giovanni Battista Pajno; Diego Peroni; Alberto Villani; Lawrence Eichenfield
Journal:  Ital J Pediatr       Date:  2022-06-14       Impact factor: 3.288

Review 2.  The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data.

Authors:  Maddalena Napolitano; Gabriella Fabbrocini; Angelo Ruggiero; Vincenzo Marino; Mariateresa Nocerino; Cataldo Patruno
Journal:  Drug Des Devel Ther       Date:  2021-03-10       Impact factor: 4.162

3.  Abnormal sperm morphology is associated with sensitization to inhaled allergens.

Authors:  Rafał Adamczak; Natalia Ukleja-Sokołowska; Magdalena Pasińska; Joanna Zielińska; Mateusz Leśny; Mariusz Dubiel
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.219

4.  Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning.

Authors:  Sara Alcantara-Luna; Ricardo Ruiz-Villaverde; Javier Domínguez-Cruz; Manuel Galán-Gutiérrez; Francisco Navarro-Triviño; Jose-Juan Pereyra-Rodriguez; Jose-Carlos Armario-Hita
Journal:  Int J Environ Res Public Health       Date:  2022-08-29       Impact factor: 4.614

5.  Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series.

Authors:  A L Bosma; L A A Gerbens; M A Middelkamp-Hup; P I Spuls
Journal:  Clin Exp Dermatol       Date:  2021-06-04       Impact factor: 3.470

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.